The global fuel cell device market was valued at USD 9.5 billion in 2025. The market is projected to grow from USD 11.97 billion in 2026 to USD 56.77 billion by 2034, exhibiting a compound annual growth rate of 21.43% during the forecast period. Contrive Datum Insights presents this information in its report titled "Fuel Cell Device Market Size, Share & Industry Analysis, By Product (GI Videoscopes, Biopsy Devices, Endoscopic Retrograde Cholangiopancreatography Devices (ERCP), Capsule Endoscopy, Endoscopic Ultrasound, Endoscopic Mucosal Resection (EMR), Hemostasis Devices, Other Product Types), Sales channel (Online Retailing, Medical Stores & Brand Outlet), End use (Hospitals, Clinics & Dialysis Centers, Ambulatory Surgical Center), Application (Diagnostic Endoscopy, Therapeutic Endoscopy), Usability (Reusable Devices, Disposable/Single-Use Devices), and Regional Forecast, 2026-2034".
A fuel cell device converts chemical energy stored in hydrogen or another fuel directly into electricity through an electrochemical reaction, producing power with water and heat as the principal byproducts rather than combustion emissions. Devices in this category range from small portable and backup power units to larger stationary systems installed at commercial, industrial and utility sites, alongside fuel cell modules integrated into transportation platforms. Buyers span utilities and industrial facilities seeking resilient backup power, commercial and residential property operators adopting distributed generation, and transportation fleet operators evaluating zero-emission drivetrains.
Rising diagnostic and therapeutic endoscopy procedure volumes
Rising diagnostic and therapeutic endoscopy procedure volumes is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 21.43% a year, the product lines exposed to it move fastest: Capsule Endoscopy compounds at 26.67%, taking its share of revenue from 9.47% to 14% and its value from USD 0.9 billion to USD 7.95 billion.
On the upside, the study's bull case assumes bull case assumes ambulatory and outpatient site-of-care migration continues at its recent pace or faster, single-use device pricing declines quickly enough to accelerate adoption, and screening-driven procedure volume keeps expanding across the largest markets without a reimbursement pullback, which would take 2034 revenue to USD 63.58 billion against the USD 56.77 billion base case.
The downside is specific. Bear case assumes capital budget constraints slow hospital replacement cycles, reimbursement policy tightens in one or more large markets, and single-use device adoption stalls as reprocessing costs prove more durable than the base case expects, and 2034 revenue lands at USD 49.96 billion. GI Videoscopes is the drag, 30.21% of the 2025 base compounding at 19.98% while the market runs at 21.43%.
Key Players Compete on GI Videoscopes Volume and Capsule Endoscopy Growth
The product axis, not the regional one, is what divides the field. GI Videoscopes is the volume position, 30.21% of 2025 revenue at USD 2.87 billion, holding 27% through 2034, and it is defended by scale. Capsule Endoscopy is the growth position at 26.67%, and it is open. Strength in one does not carry into the other.
What Else the Report Shows
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Sales channel | Medical Stores & Brand Outlet | 78% · USD 7.41 billion | Online Retailing 26.25% |
| End use | Hospitals | 58% · USD 5.51 billion | Ambulatory Surgical Center 25.34% |
| Application | Diagnostic Endoscopy | 54.95% · USD 5.22 billion | Therapeutic Endoscopy 23.94% |
| Usability | Reusable Devices | 62% · USD 5.89 billion | Disposable/Single-Use Devices 25.74% |
- Regionally, the lead sits with Asia Pacific: 38.14% of 2025 global revenue, USD 3.62 billion rising to USD 23.84 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 38.14% in 2025 to 42% in 2034, with revenue growing from USD 3.62 billion to USD 23.84 billion.
- At 5.68% of 2025 revenue and 6% by 2034, Middle East and Africa is the smallest region throughout.
- By product, the largest line in 2025 was GI Videoscopes, at 30.21% of revenue and USD 2.87 billion.
- No product line grows faster than Capsule Endoscopy, at a projected 26.67%.
- The United States is the largest single country market at USD 2.47 billion in 2025, 26% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by product, and by sales channel, end use, application and usability. The headline total carries bear, base and bull cases at USD 49.96 billion and USD 63.58 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.